See more : Koninklijke DSM N.V. (KDSKF) Income Statement Analysis – Financial Results
Complete financial analysis of Monte Rosa Therapeutics, Inc. (GLUE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Monte Rosa Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Jahez International Company for Information Systems Technology (9526.SR) Income Statement Analysis – Financial Results
- Modulight Oyj (MODU.HE) Income Statement Analysis – Financial Results
- Jiangsu Broadcasting Cable Information Network Corporation Limited (600959.SS) Income Statement Analysis – Financial Results
- Boston Omaha Corporation (BOC) Income Statement Analysis – Financial Results
- Bharat Electronics Limited (BEL.BO) Income Statement Analysis – Financial Results
Monte Rosa Therapeutics, Inc. (GLUE)
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.22M | 8.56M | 2.13M | 537.00K | 72.00K |
| Gross Profit | -6.22M | -8.56M | -2.13M | -537.00K | -72.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 105.05M | 85.06M | 57.16M | 24.01M | 7.35M |
| General & Administrative | 32.04M | 27.32M | 15.73M | 4.01M | 644.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.04M | 27.32M | 15.73M | 4.01M | 644.00K |
| Other Expenses | 0.00 | 0.00 | -960.00K | -7.68M | 276.00K |
| Operating Expenses | 143.31M | 112.38M | 72.88M | 28.01M | 7.99M |
| Cost & Expenses | 143.31M | 112.38M | 72.88M | 28.01M | 7.99M |
| Interest Income | 9.33M | 3.76M | 46.00K | 9.00K | 12.00 |
| Interest Expense | 0.00 | 3.76M | 0.00 | 0.00 | 1.00K |
| Depreciation & Amortization | 6.22M | 8.56M | 2.13M | 537.00K | 72.00K |
| EBITDA | -137.09M | -99.94M | -70.75M | -27.47M | -7.67M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -143.31M | -112.38M | -72.88M | -28.01M | -7.99M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.30M | 3.88M | -1.08M | -7.87M | 254.00K |
| Income Before Tax | -135.01M | -108.50M | -73.96M | -35.88M | -7.74M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 338.00K | -3.88M | -2.02M | 189.00K | 277.00K |
| Net Income | -135.35M | -104.62M | -71.94M | -36.07M | -8.02M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.63 | -2.22 | -1.55 | -0.82 | -0.18 |
| EPS Diluted | -2.63 | -2.22 | -1.55 | -0.82 | -0.18 |
| Weighted Avg Shares Out | 51.40M | 47.23M | 46.54M | 44.00M | 44.00M |
| Weighted Avg Shares Out (Dil) | 51.40M | 47.23M | 46.54M | 44.00M | 44.00M |
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the quarter ended June 30, 2023.
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors. Dr....
Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to present at the following investor and industry events in June:
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to participate in fireside chats and industry panels, as well as...
How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46%
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 226.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an...
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader-based medicines, today announced the company will participate in the following upcoming investor conferences:
Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium
– New and Updated Preclinical Data Highlight Potential of GSPT1-directed Molecular Glue Degrader (MGD) MRT-2359 in the Treatment of MYC-driven Cancers –
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced that the company is scheduled to present at the following upcoming investor conferences:
Monte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced that the company is scheduled to present at the virtual 40th Annual J.P. Morgan Healthcare Conference...
Monte Rosa Therapeutics to Present at 4th Annual Targeted Protein Degradation Summit
BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Sharon Townson, Ph.D., Chief Technology Officer, will present at the virtual 4th Annual Targeted Protein...
Source: https://incomestatements.info
Category: Stock Reports